JP2017535794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535794A5 JP2017535794A5 JP2017543287A JP2017543287A JP2017535794A5 JP 2017535794 A5 JP2017535794 A5 JP 2017535794A5 JP 2017543287 A JP2017543287 A JP 2017543287A JP 2017543287 A JP2017543287 A JP 2017543287A JP 2017535794 A5 JP2017535794 A5 JP 2017535794A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pif
- cells
- analog
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GLXYOFXNKBTMQL-YKCHQESGSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-methylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O)CCC1 GLXYOFXNKBTMQL-YKCHQESGSA-N 0.000 claims description 190
- 210000002865 immune cell Anatomy 0.000 claims description 142
- 238000000034 method Methods 0.000 claims description 129
- 210000004027 cell Anatomy 0.000 claims description 85
- 230000008938 immune dysregulation Effects 0.000 claims description 56
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims description 25
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims description 25
- 210000004443 dendritic cell Anatomy 0.000 claims description 24
- 201000009273 Endometriosis Diseases 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 20
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 12
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 12
- -1 PIF amino acid Chemical class 0.000 claims description 11
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000000684 flow cytometry Methods 0.000 claims description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 230000035935 pregnancy Effects 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 230000003100 immobilizing effect Effects 0.000 claims description 3
- 230000007812 deficiency Effects 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000002584 immunomodulator Effects 0.000 description 3
- 102000004899 14-3-3 Proteins Human genes 0.000 description 2
- 101000760084 Homo sapiens 14-3-3 protein eta Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- 102100038938 Myosin-9 Human genes 0.000 description 1
- 101710204108 Myosin-9 Proteins 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462074384P | 2014-11-03 | 2014-11-03 | |
| US62/074,384 | 2014-11-03 | ||
| US201562113298P | 2015-02-06 | 2015-02-06 | |
| US62/113,298 | 2015-02-06 | ||
| US201562211660P | 2015-08-28 | 2015-08-28 | |
| US62/211,660 | 2015-08-28 | ||
| PCT/US2015/050532 WO2016044493A1 (en) | 2014-09-16 | 2015-09-16 | Compositions and methods for treating acute radiation syndrome |
| USPCT/US2015/050532 | 2015-09-16 | ||
| PCT/US2015/058877 WO2016073513A1 (en) | 2014-11-03 | 2015-11-03 | Pif binding as a marker for immune dysregulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535794A JP2017535794A (ja) | 2017-11-30 |
| JP2017535794A5 true JP2017535794A5 (https=) | 2018-12-13 |
Family
ID=55909715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543287A Pending JP2017535794A (ja) | 2014-11-03 | 2015-11-03 | 免疫調節不全についてのマーカーとしてのpif結合 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180318386A1 (https=) |
| EP (1) | EP3215847A4 (https=) |
| JP (1) | JP2017535794A (https=) |
| AU (2) | AU2015343202A1 (https=) |
| CA (1) | CA2965973A1 (https=) |
| IL (1) | IL251667A0 (https=) |
| WO (1) | WO2016073513A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017039751A1 (en) | 2015-08-28 | 2017-03-09 | Bioincept, Llc | Mutant peptides and methods of treating subjects using the same |
| WO2017079430A1 (en) * | 2015-11-03 | 2017-05-11 | Bioincept, Llc | Peptides and methods of treating endometriosis using the same |
| EP3341006A4 (en) | 2015-08-28 | 2019-03-13 | BioIncept LLC | COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE |
| US20230190867A1 (en) * | 2018-02-22 | 2023-06-22 | Bioincept, Llc | Methods of treating nash and compositions therefore |
| CN113640092A (zh) * | 2020-04-23 | 2021-11-12 | 复旦大学 | 石蜡包埋组织样本的处理方法以及其质谱检测方法 |
| US20230400471A1 (en) * | 2020-10-15 | 2023-12-14 | Bioincept, Llc | Systems, compositions and methods of determining viability of embryos using the same |
| WO2025078961A1 (en) * | 2023-10-13 | 2025-04-17 | Gufic Biosciences Limited | Composition and method for treatment of endometriosis |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646003A (en) * | 1994-03-23 | 1997-07-08 | Barnea; Eytan R. | Preimplantation factor |
| ATE374370T1 (de) * | 1999-01-25 | 2007-10-15 | Siemens Medical Solutions Diag | Verfahren zur diagnose von endometriose |
| US8222211B2 (en) * | 2001-07-02 | 2012-07-17 | Bioincept, Llc | Methods of administering PIF agonist peptides and uses thereof |
| US7273708B2 (en) * | 2001-07-02 | 2007-09-25 | Bioincept, Llc | Assays for preimplantation factor and preimplantation factor peptides |
| US7723289B2 (en) * | 2003-10-22 | 2010-05-25 | Bioincept, Llc | PIF tetrapeptides |
| EP2479277B1 (en) * | 2004-07-22 | 2015-09-02 | Five Prime Therapeutics, Inc. | Use of MGD-CSF in a method of treatment of Alzheimer's disease. |
| WO2006087722A1 (en) * | 2005-02-17 | 2006-08-24 | Hadasit Medical Research Services And Development Ltd. | Bisphosphonates for treating endometriosis |
| US20070136003A1 (en) * | 2005-12-08 | 2007-06-14 | Electronics And Telecommunications Research Institute | Method and system of verifying protein-protein interaction using protein homology relationship |
| US9737585B2 (en) * | 2011-03-02 | 2017-08-22 | Bioincept, Llc | Compositions and methods for treatment of intracellular damage and bacterial infection |
-
2015
- 2015-11-03 AU AU2015343202A patent/AU2015343202A1/en not_active Abandoned
- 2015-11-03 WO PCT/US2015/058877 patent/WO2016073513A1/en not_active Ceased
- 2015-11-03 CA CA2965973A patent/CA2965973A1/en not_active Abandoned
- 2015-11-03 JP JP2017543287A patent/JP2017535794A/ja active Pending
- 2015-11-03 EP EP15856440.1A patent/EP3215847A4/en not_active Ceased
-
2016
- 2016-11-03 US US15/773,385 patent/US20180318386A1/en not_active Abandoned
-
2017
- 2017-04-09 IL IL251667A patent/IL251667A0/en unknown
-
2019
- 2019-05-16 AU AU2019203459A patent/AU2019203459A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535794A5 (https=) | ||
| JP7430136B2 (ja) | 疲弊したt細胞に関連する疾患を治療するための方法および組成物 | |
| US8647822B2 (en) | Determining whether a test compound modulates PD-1 activity in activated immune cells using gene expression profiles | |
| Roedder et al. | Biomarkers in solid organ transplantation: establishing personalized transplantation medicine | |
| US20220373538A1 (en) | Composition for determination of cell-mediated immune responsiveness | |
| TW201243328A (en) | Diagnostic and therapeutic uses for B cell maturation antigen | |
| JP2005510251A (ja) | サルコイドーシスの評価法と予後判定法 | |
| WO2016185182A1 (en) | Detection of t cell exhaustion or lack of t cell costimulation and uses thereof | |
| Mensink et al. | Tregs from human blood differentiate into nonlymphoid tissue–resident effector cells upon TNFR2 costimulation | |
| JP2021528965A (ja) | 多発性硬化症における免疫優性タンパク質および断片 | |
| US20210052593A1 (en) | Compositions and Methods for the Treatment of Macrophage Activation Syndrome | |
| Schreibing et al. | Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell epitope mapping | |
| EP1963551A1 (en) | Markers for memory t cells and uses thereof | |
| US11567065B2 (en) | Measuring frequency of pathogen-specific T cells in peripheral blood | |
| WO2021044056A1 (en) | Method for determining the effectiveness of a nanoparticle-based therapy | |
| Heikkilä et al. | Expanded CD4+ effector/memory T cell subset in APECED produces predominantly interferon gamma | |
| WO2013086304A1 (en) | Methods and compositions for diagnosing neurodegenerative disease | |
| Samani et al. | Alteration in CD8+ T cell subsets in enterovirus-infected patients: an alarming factor for type 1 diabetes mellitus | |
| KR20170089334A (ko) | 말초혈액 내의 hla-dr+ t 세포의 비율을 이용하여 신장이식환자에서 미세혈관 염증 또는 항체 매개성 거부반응을 진단하는 방법 | |
| JP2014163769A (ja) | 患者検体を用いたhtlv−1キャリア、成人t細胞白血病の発癌過程進行度又は悪性度の評価法 | |
| CN102918396B (zh) | 利用人类白血球抗原(hla)筛检预测药物不良反应的方法 | |
| Ravishankar et al. | T-cells specific for KSHV and HIV migrate to Kaposi sarcoma tumors and persist over time | |
| CN116802320A (zh) | 使用细环病毒(ttv)作为确定t淋巴细胞增殖能力的标志 | |
| US20200319164A1 (en) | Methods for detecting, assessing severity and treating multiple sclerosis | |
| Mead et al. | Integrated, high-dimensional analysis of CD4 T cell epitope specificities and phenotypes reveals unexpected diversity in the response to Mycobacterium tuberculosis |